The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro
about
Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domainThe Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activityMKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2The proximal signaling network of the BCR-ABL1 oncogene shows a modular organizationA Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicityRac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2)Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathwaysLRRK2 and the stress response: interaction with MKKs and JNK-interacting proteinsLRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowthARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutationsLRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative studyA direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylationThe Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sitesAn early endosome regulator, Rab5b, is an LRRK2 kinase substrateMembrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylationAdult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S miceLRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegansLRRK2 phosphorylates novel tau epitopes and promotes tauopathyDown-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicityMutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neuronsCurrent understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor designGenetics in Parkinson disease: Mendelian versus non-Mendelian inheritancePhosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPasesLeucine-rich repeat kinase 2 modulates retinoic acid-induced neuronal differentiation of murine embryonic stem cellsSignal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticitymTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylationERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.Receptor-interacting protein (RIP) kinase family.Recent advances in the genetics of Parkinson's disease.Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia.The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice.
P2860
Q24293453-0BA0A11F-A015-48E8-8FF6-119876B2FF40Q24293505-7D045DDE-004B-4B70-AB55-7E36580AE6E6Q24294736-AAD141A0-7923-42C7-AB45-CB3C41AD3B9CQ24294830-058C7B09-C32F-42C7-80E8-BBB7EC7B46F1Q24296968-5F3661F1-7C61-418D-B070-850402019171Q24298459-E36F8E91-4603-4D1F-B316-E03DACC56A2AQ24299578-B0A24B03-A99B-4292-86A8-3B845367F365Q24300440-55615BE8-D567-4D21-91F3-AFC6EA34E3DCQ24304347-EC63D3CB-1D9F-4270-B391-6FCA1D1CDC44Q24305448-9EAACAEB-2C40-4847-AD14-9C92002CA3A2Q24306239-36FD99FA-9841-4C24-AA5B-23D85329682EQ24307455-AC1A1D2B-27A6-4DA1-8121-202512468780Q24310126-10057466-0C80-4DD5-8EA8-6F436AB43905Q24313336-A069A8D4-C3BE-4402-954B-BF9EB142C8EEQ24315778-F4274E08-A27B-4909-8F65-9B6DE47F3381Q24316270-7026FC7C-858F-4E7E-832D-045C7BEAC644Q24317631-946CDB57-FE57-456E-9B98-28C9F452FC0DQ24317760-DE0189E7-830A-462E-9E0A-2AFBDF28B983Q24324231-1D0FA6E4-56A1-4109-9306-51A4389580D9Q24338188-CB5AB13C-B58E-4DB9-A4F6-FF622A05CE0BQ24339471-64A8DF58-FCA7-4F37-B0C2-E5D446108296Q24628425-0C5C7532-1802-4CA7-BFE6-53F609CA3F67Q26827527-E024B89A-9C0C-4C33-A80B-5DA5412587BDQ28077356-1CD4664A-0A24-4EBE-BBD2-117CD770B6E7Q28119192-2D237523-A843-4B20-AD90-13C904E94349Q28743800-6FC0705C-EC70-4C8F-B323-A261012E8E90Q28748929-E8FA4DD3-B848-4BE5-A012-245030943CAAQ28822211-BEE9BB32-95DF-4FCE-94B8-B9BA55763727Q33525587-07AE2F1B-D13A-4F3D-9843-B7DDBF19D5FAQ33593798-D2E8DDAB-CE39-4521-9DBA-924D9242217FQ33964804-62DC3755-8AB4-4AEF-8B15-72CFD665E916Q34109567-9A33E6F8-270F-4015-9A9C-1C9D1207AB25Q34189660-13C2B3AF-F653-4B7E-8F4B-1D36C6B72A99Q34230271-4E4809CA-2888-4F8A-8102-812BEF6EBF97Q34236070-A84F9089-EF37-4F5C-83BC-D80D284AB0EBQ34240711-2A3ED2AF-3B48-443E-A731-14D0864F98D2Q34300430-0368C2A5-263B-452E-9C29-72EE6F6CE944Q34452296-37555ADE-2383-40D8-AD52-A4DDF9676DB1Q34454883-80CCC858-C261-469F-BDE5-7618C1D5DE73Q34723024-4B7F6C54-E672-41C0-920A-74722CB403F9
P2860
The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@ast
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@en
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@en-gb
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@nl
type
label
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@ast
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@en
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@en-gb
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@nl
altLabel
The Parkinson disease-associat ...... tes MKK3/6 and MKK4/7,in vitro
@en
prefLabel
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@ast
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@en
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@en-gb
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@nl
P50
P921
P3181
P1476
The Parkinson disease-associat ...... es MKK3/6 and MKK4/7, in vitro
@en
P2093
Annette Schumacher
P304
P3181
P356
10.1111/J.1471-4159.2009.06024.X
P4011
c4811a74a20d78daac6edb5df3412e1e5f46ecb5
P407
P577
2009-05-01T00:00:00Z